Vol 18, No 2 2020
If there is scant evidence of dramatic shifts in the paradigm, occasionally seen during previous annual sessions, incremental progress has been sustained on many investigative fronts. continue
Robert A. Figlin, MD
Executive editor, Kidney Cancer Journal Read
KCA accepting applications for investigator awards
HOUSTON—The Kidney Cancer Associations is accepting applications for their Young Investigator Awards (YIAs) through August 5, 2020. Four $75,000 YIAs are available. Recipients will be announced in fall 2020.
YIAs encourage promising researchers in urology and clinical oncology who are planning to pursue an investigative career in kidney cancer.
The priority research areas that emerged as a result of the KCA’s Think Tank: Coalition for a Cure, held last fall in conjunction with the 18th International Kidney Cancer Symposium, included cure or durable therapeutic response, improved screening and surveillance, neoadjuvant and adjuvant treatment strategies, and non-clear cell renal cell carcinoma. All grant proposals will be evaluated by an independent panel of reviewers, who are recognized experts in the field. They will conduct a blinded, scored review of all applications received.
FDA approves additional pembrolizumab dosing strategy, 400 mg per 6 weeks
The FDA has approved an additional recommended dosage of 400 mg every six weeks (Q6W) for pembrolizumab (Keytruda), the anti-PD-1 therapy, across all adult indications, including monotherapy and combination therapy. continue